Teva Pharmaceuticals International Gmbh

Teva Pharmaceutical Industries Limited

Assia Chemical Industries Ltd.

Plus Chemicals Sa

Farmak, A.s.

Ivax International Gmbh

Roman Gabriel

Alexandr Jegorov

Pavel Vraspir

Ales Gavenda

Martin Valik

David Lukas

Judith Aronhime

Tamas Koltai

Ondrej Simo

Hana Kantor

Jirí Faustmann

Tamás Koltai

Pavel Kolesa

Jirí Filipcík

Alexandr Martaus

Adrienne Kovacsne-Mezei

Peter Lindsay MacDonald

Pavel Hradil

Pierluigi Rossetto

Martin Grepl

Petr Slezar

Lubomir Kvapil

Jan Novotny

Radek Melnicky

Tomas Holas

Jiri Faustmann

Pavel Vraspír

The present disclosure provides solid state forms of Relugolix, crystalline forms of Relugolix, pharmaceutical compositions thereof, and pharmaceutical formulations thereof. Methods for producing these forms of Relugolix, pharmaceutical compositions, and pharmaceutical formulations are also provided.

Solid state forms of Relugolix

The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.

Solid state forms of Ixazomib Citrate

The present disclosure encompasses crystalline polymorphs of Rigosertib Sodium, processes for preparation thereof, and pharmaceutical compositions thereof.

Crystalline polymorphs of Rigosertib Sodium

Solid state forms of ixazomib citrate

The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.

Solid state forms of cabazitaxel and processes for preparation thereof

The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel. The present invention further provides pharmaceutical compositions comprising one or more of the solid state forms of Cabazitaxel, and a method of treating hormone-refractory prostate cancer.

Provided are polymorphs of fluticasone furoate and processes for preparation thereof.

Polymorphs of fluticasone furoate and process for preparation thereof

The invention provides crystalline forms of isopropyl alcohol solvate of dasatinib, methods for their preparation, and pharmaceutical compositions thereof. 

Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof

A method for the preparation of salts of 2-[2-(4-dibenzo[b,fj[1,4]thiazepin-11-yl-1 -piperazinyl)ethoxy]ethanol (quetiapine) from the quetiapine base and the respective acid, wherein the salt is precipitated from a mixture of solvents, the mixture being either a mixture of an aromatic hydrocarbon and a ketone or ester, or that of an aromatic hydrocarbon, water and a ketone or ester. The salts of quetiapine are purified by partial crystallization, wherein only a part of the salt of quetiapine is dissolved in a Cto Calcohol used.

Methods for the preparation of salts of 2-[2-(4-dibenzo[B,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxyl]ethanol (quetiapine) and for the purification thereof

The invention provides anhydrous forms of dasatinib, methods for their preparation, and pharmaceutical compositions thereof. 

Anhydrous form of dasatinib and process for preparation thereof

Growing community of inventors

Olomouc, Czechia

Roman Gabriel